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Abstract
Background: Functional characterization of non-coding elements in the human genome is a major genomic
challenge and the maturation of genome-editing technologies is revolutionizing our ability to achieve this task.
Oncogene-induced senescence, a cellular state of irreversible proliferation arrest that is enforced following excessive
oncogenic activity, is a major barrier against cancer transformation; therefore, bypassing oncogene-induced senescence
is a critical step in tumorigenesis. Here, we aim at further identification of enhancer elements that are required for the
establishment of this state.
Results: We first apply genome-wide profiling of enhancer-RNAs (eRNAs) to systematically identify enhancers that are
activated upon oncogenic stress. DNA motif analysis of these enhancers indicates AP-1 as a major regulator of the
transcriptional program induced by oncogene-induced senescence. We thus constructed a CRISPR-Cas9 sgRNA library
designed to target senescence-induced enhancers that are putatively regulated by AP-1 and used it in a functional
screen. We identify a critical enhancer that we name EnhAP1-OIS1 and validate that mutating the AP-1 binding site within
this element results in oncogene-induced senescence bypass. Furthermore, we identify FOXF1 as the gene regulated
by this enhancer and demonstrate that FOXF1 mediates EnhAP1-OIS1 effect on the senescence phenotype.
Conclusions: Our study elucidates a novel cascade mediated by AP-1 and FOXF1 that regulates oncogene-induced
senescence and further demonstrates the power of CRISPR-based functional genomic screens in deciphering the
function of non-coding regulatory elements in the genome.
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Background
Over the last decade, large-scale genomic projects iden-
tified hundreds of thousands of regulatory elements
(REs) in the human genome; most of them are putative
enhancers [1, 2]. Identification of candidate enhancer re-
gions was mainly based on profiling of characteristic his-
tone modifications (e.g. H3K27ac and H3K4me1) and
binding of transcriptional activators (e.g. p300). Recently,
enhancer-RNA (eRNA) expression, typically transcribed
bi-directionally at promoter-distal cis-REs, was indicated
as a sharp feature of active enhancers and was utilized
for the systematic discovery of enhancers across the gen-
ome [3]. Importantly, changes in eRNA production cor-
relate with changes in the enhancer activity [4, 5]. Yet,
functional characterization of the plethora of candidate
enhancer elements is a major genomic challenge [6].
High-throughput reporter assays to probe the functions
of regulatory regions were developed in recent years [7].
However, these methods separate putative REs from
their native chromosome, so that any effect of chromatin
context and long range regulatory interactions is lost.
Furthermore, definitive demonstration of the function of
the RE requires their perturbation in situ. The matur-
ation of novel genome-editing technologies is
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revolutionizing our ability to interrogate the function of
the non-coding genome. This potential was demon-
strated by pioneering CRISPR-based functional genomic
screens that systematically targeted non-coding elements
in the human genome [8–11].
In one of these CRISPR-based functional genomic
screens, we focused on oncogene-induced senescence
(OIS), which is a cellular state of irreversible prolifera-
tion arrest that is enforced in face of excessive oncogenic
activity (oncogenic stress) [8]. OIS is a major barrier
against cancer transformation [12, 13]; therefore, over-
coming OIS is a critical step in tumorigenesis [14].
Activation of this process is largely dependent on p53
[13, 15]; consequently, its bypass by cancer cells is
mainly achieved by emergence of somatic mutations
(SM) in p53 or other components of its pathway [16,
17]. As p53 is an enhancer-binding transcription factor
(TF), whose function in transcriptional regulation is re-
quired for its tumor suppressive activity, we previously
performed a CRISPR-based functional genomic screen
that systematically targeted p53-bound enhancers [18].
That screen uncovered several p53-bound REs that are re-
quired for the activation of OIS. However, aberrant ex-
pression of oncogenes can lead to the activation of
additional TFs whose function is also critical for the estab-
lishment and/or maintenance of OIS. In the current study,
we aimed at the identification of such TFs and discovery
of additional enhancers that are required for the establish-
ment of OIS. We carried out an unbiased profiling of en-
hancers activated upon oncogenic stress, which indicated
AP-1 as a major regulator of the transcriptional program
induced by OIS. We thus generated a CRISPR-Cas9 single
guide RNA (sgRNA) library designed to target enhancers
putatively regulated by AP-1 and used it in a functional
screen to identify those required for OIS. This screen de-
tected EnhAP1-OIS1, an AP-1 bound enhancer that is
hyper-activated in OIS and whose abrogation results in
OIS bypass. Furthermore, we identified FOXF1 as the tar-
get gene of this enhancer and demonstrated that it regu-
lates the senescence phenotype.
Results
Genome-wide identification of OIS-induced enhancers
We previously carried out a CRISPR-based screen aimed
at identification of p53-bound enhancers that are re-
quired for OIS [17]. That screen was confined to regions
that are directly bound by p53 as detected by p53 chro-
matin immunoprecipitation-sequencing (ChIP-seq) ana-
lysis and therefore missed enhancers that are critical for
OIS enforcement and are regulated by other TFs, in ei-
ther a p53-dependent or -independent manner. To over-
come this limitation and to globally screen DNA REs
activated by OIS without being biased by preselection of
a candidate TF, we first sought to comprehensively
detect all the enhancers that are activated upon onco-
genic stress. To this goal, we utilized Global Run-On se-
quencing (GRO-seq), a nascent RNA detection method
[19], that allow robust determination of eRNA expression,
as a quantitative measure for enhancer activity [7, 8, 18].
We used a cellular system in which the oncogene RASG12V
was induced in hTERT-immortalized BJ cells (BJ-in-
dRASG12V). As these cells contain wild-type p53, oncogenic
stress results in a very potent activation of OIS and prolifer-
ation arrest [20]. Exploiting bi-directional transcription as a
hallmark of transcriptional activity at enhancers and pro-
moters [7, 21, 22], we detected 1821 REs whose activity was
induced in BJ-indRASG12V upon oncogene induction for
14 days (Fig. 1a; Additional file 1: Table S1). Next, we bioin-
formatically searched for TFs that potentially mediate the
activation of these regions by performing de novo DNA
motif enrichment analysis. Remarkably, we found that the
regulatory regions activated during the induction of OIS
were significantly enriched for the binding motif of the AP1
(FOS:JUN) TF (Fig. 1b). Overall, these results suggest an
important role for AP1 in the regulation of the transcrip-
tional response to oncogenic stress.
Therefore, we constructed a CRISPR library that sys-
tematically targets OIS-induced DNA elements that are
putatively regulated by AP1 and performed a functional
genetic screen to identify those that are required for OIS
activation. The de novo motif analysis detected 762 AP1
motifs in 638 OIS-induced REs (over-representation p
value = 1.2*10−88). We examined which of these motif oc-
currences can be targeted by CRISPR-Cas9, given the re-
quirement for the presence of the NGG PAM motif near
the AP-1 motif. WE required that the Cas9-madiated
DNA cut will occur either within the motif itself or up to
a margin of 5 nt with respect to it (Fig. 1c). Of the 638
OIS-induced REs containing AP1 motif, 398 (62%) met
this criterion, with most motifs targeted by 2–3 distinct
sgRNAs. Accordingly, we designed 840 sgRNAs that
target AP1 motifs in 398 OIS-induced REs. We cloned
these sgRNAs as a pool into pLentiCRISPRv2 vector and
generated a plasmid library referred herein as CRISPR-A-
P1-EnhLib (Fig. 1d and Additional file 1: Table S2).
CRISPR screen targeting OIS-induced enhancers with AP-1
motif
We used the CRISPR-AP1-EnhLib library to screen for
DNA elements that are putatively regulated by AP1 and
are required for the activation of OIS. BJ-indRASG12V
were transduced with four independent lentiviral pools
of CRISPR-AP1-EnhLib and selected with puromycin.
Then we treated the cells with 4-OHT (RAS induction)
or DMSO (control) as shown in Fig. 2a. Following four
weeks of culturing, we harvested the cells, isolated gen-
omic DNA, amplified integrated vectors by polymerase
chain reaction (PCR), and used next-generation
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sequencing (NGS) to quantify the abundance of inte-
grated sgRNAs present in each population. We reasoned
that sgRNAs targeting REs that are required for OIS
would cause bypass of senescence and sustained cell
proliferation, and thus would be enriched in the cell
population under oncogenic stress compared to controls
(Fig. 2a). Indeed, our screen detected several sgRNAs
that were highly enriched in the OIS population (Fig. 2b;
Additional file 1: Table S3); among them, five showed an
average enrichment fold above 1.75 over the four repli-
cates of the screen. Notably, two of these five sgRNAs,
sgRNAs-AP169 and sgRNA-AP171, are independent
sgRNAs that target the same enhancer region (Fig. 2b),
hence increasing the confidence that these are
true-positive hits. ENCODE ChIP-seq data confirmed a
strong binding of both FOS and JUN to this region
(Additional file 2: Figure S1). Moreover, our GRO-seq
data showed ~ 2-fold induction of eRNA expression
from this enhancer in response to oncogenic stress.
Thus, we selected this regulatory region for further val-
idation and functional characterization and named it
EnhAP1-OIS1.
First, using individual transductions, we validated that
the introduction of sgRNAs AP169 and AP171 to
BJ-indRASG12V cells causes a potent bypass of OIS, as
judged by cell number and morphology (Fig. 2c).
Second, we confirmed that introduction of these two
sgRNAs to BJ-indRASG12V cells indeed results in an
array of small deletions and insertions at the expected
position within the AP1 binding motif in the targeted
enhancer (Additional file 2: Figure S2). Third, following
induction of oncogenic stress, sgRNAs AP169 and AP171
transduced BJ-indRASG12V cells showed a significant re-
duction in senescent-associated-β-Gal (SA- β-Gal)
A
C
D
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Fig. 1 Design of a CRISPR screen targeting AP1 enhancers which are activated upon oncogenic stress. a An example of an enhancer whose
activity is induced in response to oncogenic stress. Enhancer activity is inferred from the typical bi-directional transcription of eRNAs (BJ + DMSO
indicates proliferating cells and BJ + 4-OHT indicates senescent cells); genomic regions that show DNase hypersensitivity (DHS), as determined by
ENCODE, are shown by the gray track). Overall, our GRO-seq analysis identified 1821 regulatory elements (REs; enhancers or promoters) whose
activity was induced in BJ cells in face of RAS activation. b De novo motif analysis detected highly significant enrichment of the FOS:JUN (AP1)
DNA motif in the REs that were induced upon oncogenic stress. Top: the enriched motif detected in our dataset; bottom: the AP1 motif from the
JASPAR DB [49]. c An example for occurrence of an AP1 motif within an enhancer that was induced upon oncogenic stress, that is located close
enough to an NGG PAM motif, resulting in Cas9-mediated DNA cleavage that occur within the motif (Cas9 cleavage occurs ~ 3 nt before the
PAM). Overall, we identified 398 induced REs with AP1 motif that met this requirement (Cas9 cleavage within a margin of 5 nt with respect to
the motif). d Statistical summary of the CRISPR-AP1-EnhLib used in our functional screen
Han et al. Genome Biology  (2018) 19:118 Page 3 of 13
AB C D
G
E F
H
Fig. 2 (See legend on next page.)
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staining (Fig. 2d, Additional file 2: Figure S3) and an
elevated BrdU staining (Fig. 2e, Additional file 2:
Figure S3), indicative of attenuated activation of cellular
senescence and of sustained cellular proliferation com-
pared to the NT control. As expected, while the effect
caused by these two sgRNAs was highly significant, it was
not as strong as the effect elicited by targeting p53 (Fig. 2d
and e). Last, we examined the activity of EnhAP1-OIS1 fol-
lowing the transduction of sgRNAs AP169 and AP171 by
measuring eRNA expression at the EnhAP1-OIS1 locus. As
expected, targeting EnhAP1-OIS1 by these two sgRNAs sig-
nificantly compromised its activity during OIS compared
to the control sgRNA (Fig. 2f).
Next, we carried out in vitro reporter assays to verify
that EnhAP1-OIS1 functions as an enhancer and promotes
the transcription of target genes. We cloned EnhAP1-OIS1
downstream of the Firefly luciferase gene in two orienta-
tions in the pGL3-promoter vector followed by transfec-
tion into BJ-indRASG12V cells. While we did not observe
a noticeable elevation of luciferase activity in cells
treated with DMSO, there was a significant increase of
threefold in cells treated with 4-OHT (Fig. 2g). To verify
that mutations in the AP1 binding site disrupts the en-
hancer activity, as we observed in sgRNA-AP169/71 cells,
we mutated the AP1 motif of EnhAP1-OIS1 and examined
the effect on the enhancer activity, under the condition
of oncogenic stress. Indeed, the mutations completely
abolished the ability of EnhAP1-OIS1 to stimulate lucifer-
ase expression (Fig. 2h). In addition, we searched for
tumor SMs within the AP1 binding motif (using ICGC
data) and found one case in a lung cancer patient (Add-
itional file 2: Figure S4). The mutation is a C to A substi-
tution within the consensus motif of AP1 and located at
the cut site of sgRNA-AP169. To examine whether this
SM disrupts the activity of EnhAP1-OIS1, we performed
mutagenesis of EnhAP1-OIS1 on the reporter construct
with a single nucleotide substitution. Remarkably, we
observed a 50% reduction of the enhanced luciferase ac-
tivity (Fig. 2h), suggesting an important role of the speci-
fied nucleotide in determining binding affinity of AP1 to
this enhancer. Taken together, our functional genetic
screen and subsequent focused experiments have identi-
fied and validated a novel AP1-bound enhancer whose
activity is required for proper induction of OIS.
FoxF1 is a target gene of EnhAP1-OIS1
Next, we set up experiments to elucidate the mode of
action by which EnhAP1-OIS1 is required for OIS.
Enhancers regulate gene expression of cis-located target
genes that can reside hundreds of kbp away. Examin-
ation of our GRO-seq data indicated that FOXF1, the
nearest gene to the EnhAP1-OIS1 locus (located > 100 kbp
downstream of it), was approximately twofold induced
following oncogenic stress (Fig. 3a), suggesting a poten-
tial functional connection. No other gene in a 1-Mbp
distance from EnhAP1-OIS1 showed such a strong effect.
Furthermore, we performed RNA-sequencing (RNA-seq)
with cells transduced with sgRNA-AP169 and
sgRNA-AP171 and observed a significant reduction in
the expression of FOXF1 (Additional file 2: Figure S5).
We validated this result using quantitative reverse tran-
scription PCR (qRT-PCR) analysis, which also indicated
that targeting EnhAP1-OIS1 by either sgRNA-AP169 or
sgRNA-AP171 results in a significant reduction in the ex-
pression level of FOXF1 under OIS conditions (Fig. 3b).
Western blotting analysis confirmed this result at the pro-
tein level, in addition to confirming that FOXF1 expres-
sion is increased following oncogenic stress (Fig. 3c).
Publicly available RNA Pol II ChIA-PET data (from Hela
cells) indicate physical interaction between EnhAP1-OIS1
and the 3′ region of FOXF1 (Additional file 2: Figure S6),
which was confirmed in the chromatin conformation
(See figure on previous page.)
Fig. 2 Functional CRISPR screen discovers a novel enhancer required for OIS. a Schematic representation of the set-up of our functional screen. b
Results of the CRISPR screen. sgRNAs are sorted by the enrichment score based on the ratio between their prevalence in the BJ + 4-OHT and BJ
+ DMSO control populations (measured 4 weeks after 4-OHT treatment). Y-axis shows Z scores of the mean sgRNA enrichment scores (calculated
over the four replicates of the screen). Colored in red are two sgRNAs, sgRNA-AP169 and sgRNA-AP171, that target the same enhancer, called here
EnhAP1-OIS1 c Individual transductions of sgRNA- AP169 and sgRNA-AP171 validated that they cause OIS bypass. sgRNA targeting p53 was used as a
positive control and a non-targeting (NT) sgRNA was used as a negative control. d Targeting EnhAP1-OIS1 by either sgRNA-AP169 or sgRNA-AP171
caused OIS bypass as measured by β-gal staining, a canonical mark for senescence (p53ko used as a positive control). Data shown represent
mean (SD), n = 4. *p < 0.05. e Targeting EnhAP1-OIS1 by either sgRNA-AP169 or sgRNA-AP171 resulted in enhanced proliferation as measured by BrdU
staining (p53ko used as a positive control). Data shown represent mean (SD), n = 4. *p < 0.05. f Measurement of eRNA production at EnhAP1-OIS1 in
cells with the indicated sgRNAs. eRNA levels are significantly decreased upon mutagenesis of the AP1 binding site caused by either sgRNA-AP169
or sgRNA-AP171. Data shown represent mean (SD), n = 3. *p < 0.05. g BJ-indRASG12V cells were transfected with the indicated plasmids and treated
with DMSO or 4-OHT for 72 h. pGL3 constructs contain firefly luciferase reporter gene with the corresponding enhancer (none for pGL3-promoter, two
different orientations for EnhAP1-OIS1). Relative luciferase activity is calculated by dividing the firefly luciferase activity to that of Renilla
luciferase. Normalized luciferase activity is calculated by dividing the relative luciferase activity to that of pGL3-promoter for each condition.
Data shown represent mean (SD), n = 6. *p < 0.05. h BJ-indRASG12V cells were transfected with the indicated enhancer constructs. Endogenous
motif represents the original sequence of EnhAP1-OIS1, in vitro mutation construct represents mutagenesis of the AP1 consensus motif, and
MU44835851 represents mutant construct bearing a C > A mutation as indicated. The cells were treated with 4-OHT for 48 h before transfection. Data
shown represent mean (SD), n = 3. *p < 0.05
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Fig. 3 FOXF1 is the target gene regulated by EnhAP1-OIS1. a UCSC screenshot of GRO-seq analysis of BJ-indRASG12V cells. BJ cells were treated with
DMSO or 4-OHT for 14 days. Bi-directional transcription is represented by using positive and negative values for expression in the Crick and Watson
strands, respectively. The genomic regions of EnhAP1-OIS1 and FOXF1 are enlarged. Note the enhancement in GRO-seq signal for both EnhAP1-OIS1 and
FOXF1 in BJ + 4-OHT (brown track) compared to BJ + DMSO (blue track). b mRNA levels of FOXF1 are reduced in sgRNA-AP169 and sgRNA-AP171
targeted cells under 4-OHT treatment. Data shown represent mean (SD), n = 3. *p < 0.05. c BJ-indRASG12V cells transduced with the specified sgRNAs
were treated with DMSO or 4-OHT for 14 days; FOXF1, p21, and HRas protein levels were measured by western blot. HSP90 was used as the loading
control. The band of FOXF1 is marked with an arrow. ER-HRas indicates the induced version of HRas. d Targeting the FOXF1 and p53 genes caused OIS
bypass as measured by β-gal staining. Note the stronger effect of FOXF1ko compared to the effect elicited by targeting EnhAP1-OIS1 (Fig. 2d). Data
shown represent mean (SD), n = 4. *p < 0.05. e Targeting FOXF1 and p53 gene resulted in enhanced proliferation as measured by BrdU staining. Data
shown represent mean (SD), n = 4. *p < 0.05
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capture (3C) experiments of senescent BJ cells (Additional
file 2: Figure S7). More importantly, the physical interac-
tions between EnhAP1-OIS1 and the promoter region of
FOXF1 were significantly stronger (Additional file 2:
Figure S7), suggesting a robust transcriptional regulation
of EnhAP1-OIS1. Collectively, these results strongly point to
FOXF1 as the target gene of EnhAP1-OIS1.
Loss of FOXF1 causes senescence bypass and abolishes
senescence expression signatures
To further establish FOXF1 as the target gene that links
EnhAP1-OIS1 to senescence, we examined the phenotypic
effect of knocking out FOXF1. Indeed, targeting FOXF1
results in a strong senescence bypass phenotype, as
evident by significant reduction in SA-β-Gal staining
(Fig. 3d) and elevated BrdU staining (Fig. 3e), similar to
the effect elicited by targeting EnhAP1-OIS1 (Fig. 2e and f).
Effective FOXF1 knockout was confirmed by western blot-
ting analysis (Fig. 3c). Last, we used RNA-seq to globally
compare expression profiles in BJ-indRASG12V cells trans-
duced with either sgRNAs targeting EnhAP1-OIS1
(sgRNA-AP169 or sgRNA-AP171), sgRNA targeting FOXF1,
or a control non-targeting sgRNA. Gene-set enrichment
analysis (GSEA) [23] for functional characterization of the
biological processes affected by these genetic manipulations
showed that cell-cycle genes and genes encoding ribosomal
proteins are significantly upregulated when targeting either
EnhAP1-OIS1 or FOXF1, reflecting the bypass of OIS and the
subsequent enhanced proliferation experienced by these
cells following oncogene hyperactivity (Fig. 4). Conversely,
the induction of various extracellular matrix (ECM) compo-
nents that is exhibited in OIS was largely attenuated in cells
with EnhAP1-OIS1 or FOXF1 knockouts (Fig. 4). Taken to-
gether, our results strongly indicate that EnhAP1-OIS1 controls
OIS through the regulation of FOXF1 expression (Fig. 5).
Discussion
In this study, we first found that OIS-induced enhancers
are enriched for the binding motif of AP1. Based on this
finding, we perform a CRISPR screen focused on AP1
motifs within enhancers that are activated upon onco-
genic stress. We discovered a novel AP-1 bound enhan-
cer, EnhAP1-OIS1, that is required for establishment of
OIS and identified FOXF1 as the target that mediates
this role. We propose a new role of AP1 in senescence
via activation of FOXF1, providing an additional regula-
tion of cell proliferation during senescence.
AP1 TFs are recruited to enhancer regions to drive
oncogenic growth [24] and are broadly required for en-
hancer selection [25], suggesting a possible role of AP1
at enhancers. As a downstream target of RAS signaling
pathway, AP1 is activated to target mitogen-responsive
genes [26, 27]. Earlier studies have shown that messen-
ger RNA (mRNA) level and activity of AP1 genes are
attenuated upon entering replicative senescence [28, 29].
Altered AP1 activity is mainly due to loss of c-FOS ex-
pression and maintained JUN proteins, thus promoting
JUN-JUN homodimers instead of FOS-JUN heterodi-
mers [29, 30]. This suggests that loss of AP1 activity is
possibly responsible for the irreversible growth arrest in
senescent cells. Conversely, overexpression of c-FOS
with increased AP1 activity is not sufficient to initiate
DNA synthesis in senescent human fibroblasts [31].
Therefore, AP1 is likely not the key factor that regulates
senescence, but rather a downstream factor that
fine-tunes the senescence program under replicative
stress (e.g. H-RAS activation). In addition, previous
functional genetic screens did not indicate any of the
AP1 family members as critical factors in OIS [20, 32].
Supporting this conclusion, CRISPR-mediated KOs of
c-FOS and c-JUN did not result in any obvious bypass of
OIS (Additional file 2: Figure S8). However, it is possible
that one or few targets of AP1 mediate OIS while others
antagonize it or are required for cell survival.
FOXF1 belongs to the Forkhead family of TFs. FOXA1
has been reported to promote senescence via activation
of p16INK4a [33] and FOXO4 inhibition induces p53 nu-
clear exclusion, which results in apoptosis of senescent
cells [34]. The functions of FOXF1 remain to be deter-
mined, yet recent studies have implicated its role in lung
regeneration by targeting genes of ECM and cell cycle
progression [35], as well as promoting prostate cancer
growth via the MAPK pathway [36]. To date, there has
been no evidence of any connections between AP1,
FOXF1, and OIS, possibly due to regulation via en-
hancers, rather than proximal promoters, as proposed in
this study. It has been proposed that FOXF1 is a target
gene of p53, which regulates cell migration and invasion
[37]; and that FOXF1 is a potential oncogene, which
promotes rhabdomyosarcoma by repressing p21Cip1 [38].
Here, we provide the first evidence suggesting that
FOXF1 is a potential tumor suppressor, regulating senes-
cence in human cells. In addition, we generated double
knockout cell lines (NT + p53 ko, sgRNA-AP169+ p53 ko,
sgRNA-AP171+ p53 ko, and FOXF1 ko + p53 ko) and we
observed a strong senescence bypass phenotype (Additional
file 2: Figure S9). Interestingly, we found an additive effect
of proliferation in the EnhAP1-OIS1 ko and FOXF1 ko cell
lines (sgRNA-AP169+ p53 ko, sgRNA-AP171+ p53 ko, and
FOXF1 ko + p53 ko) compared with NT+ p53 ko cells
(Additional file 2: Figure S9). This suggests that FOXF1 reg-
ulates OIS in a p53 independent manner. In parallel with
the canonical p53 pathway, FOXF1 regulates the expression
of a subset of cell cycle and ribosomal genes (Fig. 4).
Further studies should explore the exact function of FOXF1
in regulating senescence.
We propose a model in which following oncogenic
induction, AP1 TFs are activated to promote cellular
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proliferation in response to stimuli. However, under
excessive exposure to RAS, AP1 is recruited to EnhA-
P1-OIS1 to promote the expression of FOXF1 to drive
cells into senescence. Disruption of the AP1 binding
site within EnhAP1-OIS1 results in attenuated activation
of FOXF1, hampering full execution of the OIS pro-
gram. We attempted to generate a FOXF1 overexpres-
sion cell line while targeting EnhAP1-OIS1, to rescue the
senescence phenotype. However, this was not success-
ful, possibly due to the intolerance of the cells under
ectopic FOXF1 expression. This result shows that al-
though AP1 is activated by the MAPK pathway and
stimulates the expression of many cell cycle genes,
upon oncogenic stress it also mediates tumor suppres-
sive effects.
Our current knowledge on cancer driver non-coding
SMs is still very rudimentary, yet several studies sug-
gested that the role of such SMs is underappreciated
[39, 40]. Genome-wide analysis has revealed AP1 as a
key factor at REs in cancers [41] and AP1 binding sites
are frequently mutated in various cancer types [42].
Analyzing ICGC data, we found a SM within the AP1
motif of EnhAP1-OIS1 in a lung cancer patient and vali-
dated its functional effect by using in vitro reporter as-
says (Fig. 2h). This suggests a possible cancer driver
effect for SMs in AP1 binding motifs. Our study further
Fig. 4 EnhAP1-OIS1 and FOXF1 knockouts display expression profiles of senescence bypass. GSEA analysis of expression profiles measured in 4OHT-
treated BJ-indRASG12V cells targeted by sgRNA-AP169, sgRNA-AP171, or sgRNA-FOXF1 compared to the profile of control 4OH-treated cells transduced
with non-targeting sgRNA. A list of shared genes within each group is shown
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demonstrates the power of CRISPR-based screens in
exploring the function of the non-coding genome.
Conclusions
Our study provides evidence that AP1 TFs are broadly
stimulated during OIS and are localized to enhancer re-
gions to activate specific gene programs. We show that
AP1 controls the senescence program via EnhAP1-OIS1
and its target gene FOXF1. We propose that AP1 is a
double-edged sword in regulating cell proliferation and
senescence, providing a restrictive feedback on unlimited
cell proliferation.
Methods
Cell culture
BJ/ET/RasV12and HEK293-T cells were cultured in
DMEM medium (Gibco), supplemented with 1% penicil-
lin/streptomycin (Gibco) and 10% FCS (Hyclone). To in-
duce OIS, BJ cells were treated with 100 nM 4-OHT
(Sigma) for 14 days.
Analysis of GRO-seq data
GRO-seq was applied to control and RASG12V-induced
hTERT immortalized BJ cells (14 days after RAS induc-
tion). These conditions were probed using biological du-
plicates. Sequenced reads were aligned to the human
genome (hg19) using bowtie2 [43]. Transcriptional units
(TUs) were inferred from the GRO-seq data using
HOMER [44]. Read counts per TU were calculated using
HTseq-count [45]. A total of 76,200 TUs covered by at
least 20 reads in at least one sample were detected. TU
expression levels were then normalized using quantile
normalization to allow comparison between samples and
fold-change (FC; presented in log2 base) was calculated
between the RAS-induced and control samples. To avoid
inflation of high FC value for lowly expressed TUs, we
set a floor value of 10 (that is, all expression levels < 10
were set to 10). Next, we defined bi-directional TUs as
TUs whose start site is separated by no more than
800 bp and are transcribed on opposite strands
(TU+ and TU-). As bi-directional transcription is a hall-
mark of transcriptional REs, we refer to these loci as REs.
Overall, this analysis defined 36,497 REs. Last, a RE
(bi-directional TU) was defined as OIS-induced if the ex-
pression level of both its mates was elevated by at least
twofold upon RAS induction, in both duplicates. In total,
1821 OIS-induced REs were identified in our dataset
(Additional file 1: Table S1).
Motif enrichment analysis
The sequences of the OIS-induced REs were searched
for statistically over-represented TF-binding motifs. We
performed this de novo motif analysis using DREME
[46]. For each bi-directional TU, we scanned the region
between the start site of the opposite mates (TU+ and
TU-) plus a margin of 200 bp to each direction. As con-
trol sequences, we extracted adjacent sequences of the
same length immediately upstream and downstream
from the test sequence. The binding motif of JUN/FOS
was highly enriched (p = 1.2*10−88) on the OIS-induced
REs. Specific occurrences of the enriched JUN/FOS
motif were identified using FIMO with default parame-
ters [47]. Overall, 762 JUN/FOS motif occurrences were
found on 638 OIS-induced REs.
CRISPR library construction and analysis
We designed a CRISPR library to target the FOS/JUN
motifs in the OIS-induced REs. For 398 of the 638
OIS-induced REs with the FOS/JUN motif, we found an
occurrence of the NGG PAM in a location that is
A B
Fig. 5 Model of EnhAP1-OIS1 regulation of OIS. a In normal BJ fibroblast cells, hyper-activation of RAS induces MAPK signaling cascade, including
AP-1 TFs. Activated AP-1 TFs control different cellular functions, including cell proliferation and apoptosis. AP1 is recruited, among other enhancers, to
EnhAP1-OIS1 and stimulates its activity. This, in turn, promotes the expression of the target gene FOXF1, diverting oncogenic signals into the pre-senescent
pathway. b Mutagenesis of the AP-1 binding site in EnhAP1-OIS1 abrogates its enhancer activity and thus leads to decreased expression of FOXF1. This results
in compromised induction of OIS and thus cells continue uncontrolled cell proliferation [52]
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expected to induce a Cas9 DNA cleavage within a mar-
gin of 5 bp with respect to the motif (that is, the cut is
expected to occur within the motif or up to 5 bp from
its edges). Overall, we designed 840 distinct sgRNAs,
collectively targeting the FOS/JUN motif in 398
OIS-induced REs. We cloned these sgRNAs into a
pLentiCRISPRv2 vector and generated a plasmid library
(which we call CRISPR-AP1-EnhLib). Induced and
control BJ-indRASG12V were transduced with four
independent lentiviral pools of CRISPR-AP1-EnhLib.
Following four weeks of culturing, we harvested
library-transduced cells, isolated genomic DNA, ampli-
fied integrated vectors by PCR, and used NGS to quan-
tify the abundance of integrated sgRNAs present in each
population. Read counts were normalized to 1 M reads
and enrichment ratios (FC in log2) were calculated for
each sgRNA between the induced and control samples
per replicate. (To avoid inflation of FC for sgRNAs cov-
ered by low number of reads, counts < 50 were set to
50). Next, average enrichment factor was calculated per
sgRNA over the four replicates and was transformed to
a Z score (Fig. 2b, Additional file 1: Table S3).
Senescence-associated β-galactosidase assay
BJ cells were transduced with different sgRNA constructs
and selected with puromycin. After selection, cells were
seeded in triplicate in six-well plates and treated with
100 nM 4-OHT for 14 days. β-galactosidase measurement
was performed by following the protocol of the Senes-
cence β-Galactosidase Staining Kit (Cell Signaling) and at
least 1000 cells were analyzed for each condition.
BrdU proliferation assay
BJ cells were seeded in six-well plates on day 1. The next
morning, cells were incubated in fresh medium for 3 h
with 30 μM bromodeoxyuridine (BrdU, Sigma) followed
by two washes with phosphate-buffered saline (PBS) and
then fixed with 4% formaldehyde. Cells were washed twice
with PBS and treated with 5 M HCl/0.5% Triton to de-
nature DNA. Cells were neutralized with 0.1 M Na2B4O7.
The cells were then treated with blocking buffer (3% BSA
in 0.5% Tween PBS) for 30 min and incubated with
anti-BrdU antibody (Dako) with blocking buffer for 2 h at
room temperature. Cells were washed with PBS three
times and finally incubated with FITC-conjugated
anti-mouse Alexa Fluor 488 secondary antibody (Dako) in
blocking buffer for 1 h, washed three times, and stained
with propidium iodide for 30 min. BrdU incorporation
was measured by immunofluorescence (at least 1000 cells
were scored for each condition). The numbers of individ-
ual nuclei and BrdU-stained nuclei were counted using
imageJ software.
Luciferase reporter assay
The constructs with the enhancers were cloned based on
pGL3-promoter (Promega) vector. The enhancer region
was PCR amplified from BJ genomic DNA and inserted
downstream of the firefly luciferase reporter gene. The
transfection was performed by seeding 1 × 105 of cultured
cells in six-well plates. The next day, 500 ng of each
construct (pGL3-promoter, pGL3-EnhAP1-OIS1-Fw, and
pGL3-EnhAP1-OIS1-Rv) were co-transfected with 50 ng of
Renilla luciferase reporter construct using Fugene-6
(Promega) following the manufacturer’s protocol. Lucifer-
ase reporter assay was performed 24 h after transfection
using a Dual-Luciferase Reporter assay kit (Promega).
Cells were lysed directly on the plate with passive lysis
buffer for 15 min at room temperature. Firefly and Renilla
luciferase activity were measured with the substrates from
the kit using Centro XS3 LB960 machine (Berthold
Technologies). For BJ-indRASG12V, cells were pre-treated
with 100 nM 4-OHT for 48 h before transfection. For
HCT116, cells were treated with UV-C (50 J/m2) or
MG132 (5 μM) 18 h after transfection. The luciferase
assay was performed 5 h after treatment.
Mutagenesis of EnhAP1-OIS1
Mutations of EnhAP1-OIS1 were performed using
QuikChange Lightning site-directed mutagenesis kit
(Agilent) according to the manufacturer’s manual.
Briefly, primers for mutagenesis were designed using the
online tool from Agilent. pGL3-EnhAP1-OIS1-Fw and
pGL3-EnhAP1-OIS1-Rv were PCR amplified and trans-
formed into DH5α bacteria. Single colonies from each
mutant were sequence verified and used for transfection.
RNA isolation, reverse transcription, and qRT-PCR
Total RNA was extracted using TRIsure (Bioline) re-
agent and following the manufacturer’s protocol. Reverse
transcription was done with SuperScript III (Invitrogen)
using 1 μg of total RNA per reaction. qRT-PCR was per-
formed using a SensiFAST SYBR No-ROX Kit (Bioline)
in LightCycler 480 (Roche). Primers used are listed in
Additional file 1: Table S4.
Western blot
A total of 1 × 106 cells were seeded in a 10-cm dish and
treated with DMSO or 4-OHT for 14 days. Cells were
trypsinized and cell pellets were lysed with RIPA buffer
supplemented with 1× complete protease inhibitor cock-
tail (Roche) following the manufacturer’s protocol.
Protein concentrations were determined using a Pierce
BCA protein assay kit (Thermo Scientific). Lysates were
separated on SDS-PAGE gels and transferred.
Membranes were immunoblotted with the following
antibodies: CDKN1A (Sc-397, Santa Cruz; 1:1000);
HRAS (C-20, Santa Cruz; 1:1000); FoxF1 (ab168383,
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Abcam, 1:1000); and HSP90 (610,418, BD Biosciences,
1:3000). Protein bands were visualized using correspond-
ing secondary antibodies (Dako) and ECL reagent (GE
Healthcare).
Lentiviruses production and infection
HEK293T cells were seeded at the density of 5 × 106
cells per 10-cm dish one day before transfection. Trans-
fection was performed using PEI (Polyethylenimine,
Polysciences) and medium was refreshed after 16 h.
Virus-containing supernatant was collected 48 h after
transfection by filtering through a 0.45-μm membrane
(Milipore Steriflip HV/PVDF) and snap-frozen, stored at
− 80 °C. BJ cells were infected and selected with the
proper antibiotics 48 h after transduction for at least
four days until no surviving cells remained in the
no-transduction control plate.
Chromatin conformation capture (3C) analysis
A total of 10 × 106 cells were harvested in PBS for each 3C
sample. Cells were centrifuged at 300 × g for 5 min at RT
and resuspended in PBS/10% FBS. Cells were then incu-
bated with an equal volume of 4% formaldehyde (2% end
concentration) for 10 min and quenched with 2 M glycine
solution (0.2 M end concentration), followed by centrifu-
gation at 300 × g for 5 min at 4 °C. The cell pellet was
then resuspended in PBS/10% PBS and centrifuged at 300
× g for 5 min at 4 °C. The supernatant was then discarded
and snap-frozen, stored at – 80 °C. The cell pellet was
lysed in 3 mL lysis buffer (50 mM Tris-HCl pH 7.5, 0.5%
NP-40, 1% Triton X-100, 150 mM NaCl, 5 mM EDTA,
protease inhibitor cocktail [Roche]) for 1.5 h at 4 °C,
followed by centrifugation at 1000 × g for 3 min. The pel-
let was washed once in 1.2× restriction buffer and resus-
pended again in 500 μL of 1.2× restriction buffer. A total
of 15 μL of 10% SDS was added to the suspension and in-
cubated at 37 °C while shaking at 400 rpm. In total, 75 μL
of 20% Triton X-100 was added to the suspension and in-
cubated at 37 °C while shaking at 400 rpm. The samples
were then centrifuged at 1000 × g for 3 min and resus-
pended in 500 μL of 1× restriction buffer. The digestion
was performed with addition of 200 U of Csp6I (Thermo
Fisher Scientific) at 37 °C overnight. The digestion effi-
ciency was assessed the next day on agarose gel. The en-
zyme was then inactivated at 65 °C for 20 min and then
samples were centrifuged at 1000 × g for 3 min to remove
the restriction buffer. The pellet was resuspended in 7 mL
of 1× ligation buffer and the ligation was performed with
addition of 50 U of T4 DNA ligase at 16 °C overnight.
Again, the ligation efficiency was examined on agarose gel.
De-crosslinking was performed by the addition of 30 μL
of protease K (Roche) at 65 °C overnight. To remove re-
sidual RNA, 15 μL of RNaseA cocktail (Ambion) was
added to the samples and incubated at 37 °C for 45 min.
DNA was recovered by adding 7 mL of isopropanol and
70 μL of NucleoMag 96 PCR beads (Bioke) and incubated
for 30 min at room temperature. The samples were centri-
fuged for 3 min at 1000 × g and washed with 80% ethanol
twice. Finally, the beads were dried and eluted in 300 μL
of 10 mM Tris-HCl pH 7.5. To assess the physical interac-
tions between EnhAP1-OIS1 and target regions, we designed
a constant primer (C1) that amplifies the EnhAP1-OIS1 re-
gion overlapping the junction created by Csp6I enzyme.
For each assessed region, we designed two primers (re-
verse and forward) to examine the interactions with EnhA-
P1-OIS1. The first PCR was performed with primer C1 and
each candidate primer for 25 cycles. Afterwards, a nested
PCR was performed using a second constant primer (C2)
and each candidate primer for another 18 cycles. Finally,
PCR products were resolved on 2% agarose gel. To assess
the primer efficiency, we PCR amplified the genomic re-
gions of EnhAP1-OIS1 and FOXF1, mixed equal molar of
each fragments as the template, digested, and ligated as
mentioned. Finally, the quantifications were normalized
with the primer efficiencies. To examine the sequences of
the PCR products, DNA bands were cut, isolated, and
sanger-sequenced.
Mutation analysis of enhancer regions
Genomic DNA of the cells transduced with sgRNAs
were isolated and quantified. A total of 500 ng of the
genomic DNA was used for PCR to amplify the enhan-
cer region. We performed a two-step PCR by introdu-
cing the P5 adapter sequences in the first PCR and P7
adapters with the indexes in the second PCR. After the
second PCR, the libraries were purified with CleanPCR
beads (CleanNA) and quantified on 2100 Bioanalyzer
using a 7500 chip (Agilent). Equimolar of each sample
was taken for the final library. Libraries were sequenced
using the Mi-Seq platform. Sequenced reads were
aligned to the amplified enhancer region using bowtie.
Bam files were analyzed to count the number of muta-
tions (mismatches, insertions, or deletions) identified at
each location in that region.
RNA-seq library construction
Total RNA was isolated using Trisure reagent (Bioline)
following the manufacturer’s protocol. Briefly, cells were
lysed in Trisure, precipitated with isopropanol, and dis-
solved in RNase-free water. To generate strand-specific
libraries, we used the TruSeq Stranded mRNA sample
preparation kit (Illumina) following the manufacturer’s
instructions. Briefly, 1000 ng of total RNA was
polyA-enriched using oligo-dT beads and the RNA was
fragmented, random primed, and reverse transcribed
using SuperScript II Reverse Transcriptase (Invitrogen).
Second strand complementary DNA was then synthe-
sized, 3’-adenylated and ligated to Illumina sequencing
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adapters, and subsequently amplified by 12 cycles of
PCR. The sequencing libraries were analyzed on a 2100
Bioanalyzer using a 7500 chip (Agilent) and pooled equi-
molar into a 10-nM multiplex sequencing pool.
Sequencing
Sequencing of the CRISPR screen and RNA-seq were
done using single reads of 65 bp on the Hi-Seq2500 plat-
form (Illumina). Mutation analysis of enhancer regions
was performed with single reads of 150 bp on the
Mi-Seq system with a Mi-Seq reagent v2 Nano kit.
RNA-seq analysis
Gene expression profiles were recorded in BJ-indRASG12V
(14 days after RAS induction by 4-OHT treatment) trans-
duced with CRISPR vectors that either targeted the EnhA-
P1-OIS1 using sgRNA-AP169, sgRNA-AP171, targeted
FOXF1 itself, or transduced with a control non-targeting
sgRNA (sgRNA-NT). Sequenced reads were aligned to the
human genome (hg19) using TopHat2 [48]. The number
of reads mapped to each annotated gene was counted
using HTseq-count [45] and then converted to RPKMs
(using GENCODE v25 annotations). RPKM levels were
further normalized using quantile normalization and ex-
pression levels in each sample relative to the control
non-targeting sample were calculated (in log2 base).
Biological pathways and processes affected by targeting
the EnhAP1-OIS1 or FOXF1 were sought using GSEA [23].
Additional files
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